Search
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalOn September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approved[L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573] … It works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT).
Categories: Compounds used in a research, industrial, or household settingVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalThe drug is not yet fully approved for this condition.[L45849] … [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Categories: Experimental Unapproved Treatments for COVID-19Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the
Nuclear factor NF-kappa-B
go.drugbank.com/bio_entities/BE0004903TargetHumansThe dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity … The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity
Synonyms: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Homatropine
go.drugbank.com/drugs/DB11181Approveduse has not been approved by the FDA to be safe and effective. … It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions.
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose. … It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same
Categories: MATE 2-K InhibitorsVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … approved for the treatment of achondroplasia in both regions.
Categories: Drugs for Treatment of Bone DiseasesLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigational[A260286] Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012. … Linaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist.
Categories: Drugs for Constipation